Background
Pancreas adenocarcinoma (PC) is a challenging disease with overall single digit 5-year survivorship. Few validated biomarkers exist for directing treatment in PC. Only one targeted agent (erlotinib) is FDA approved and was developed in an unselected population (Moore, et al, J Clin Oncol, 2007). Identification of individual PC genomic and phenotypic profiles may yield targets with novel therapeutic application.